Payment overview · 2025
General Payments
$560.61
28 reported records · 12 companies
Healthcare provider profile · identity verified
Devender Reddy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARIETTA, GA · NPI 1366415028
Verified facts
What the public records show
CMS Open Payments records show Devender Reddy, MD received $560.61 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.10 | 22.3% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $100.63 | 17.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.02 | 9.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.66 | 9.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.47 | 8.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.18 | 8.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.88 | 7.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.18 | 3.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.43 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.81 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.62 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.63 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.61 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.10 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $100.63 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.88 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.47 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.47 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 882 | 287 |
| Amlodipine Besylate | Amlodipine Besylate | 596 | 204 |
| Lisinopril | Lisinopril | 471 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 137 |
| Losartan Potassium | Losartan Potassium | 410 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 91 |
| Metformin Hcl | Metformin Hcl | 246 | 78 |
| Alprazolam | Alprazolam | 232 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 58 |
| Gabapentin | Gabapentin | 191 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 73 |
| Simvastatin | Simvastatin | 190 | 62 |
| Metformin Hcl Er | Metformin Hcl | 187 | 63 |
| Omeprazole | Omeprazole | 186 | 63 |
| Allopurinol | Allopurinol | 173 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 63 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 50 |
| Carvedilol | Carvedilol | 135 | 43 |
| Jardiance | Empagliflozin | 124 | 31 |
| Bupropion Xl | Bupropion Hcl | 119 | 34 |
| Trazodone Hcl | Trazodone Hcl | 118 | 43 |
| Meloxicam | Meloxicam | 116 | 45 |
| Sertraline Hcl | Sertraline Hcl | 109 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 39 |
| Atenolol | Atenolol | 101 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 41 |
| Clonazepam | Clonazepam | 87 | 21 |
| Januvia | Sitagliptin Phosphate | 83 | 20 |
| Tramadol Hcl | Tramadol Hcl | 81 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 25 |
| Donepezil Hcl | Donepezil Hcl | 76 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 27 |
| Montelukast Sodium | Montelukast Sodium | 74 | 26 |
| Telmisartan | Telmisartan | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Synthroid | Levothyroxine Sodium | 64 | 22 |
| Eliquis | Apixaban | 63 | 16 |
| Lorazepam | Lorazepam | 63 | 16 |
| Mounjaro | Tirzepatide | 61 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 19 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Benazepril Hcl | Benazepril Hcl | 51 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 46 |
| Spironolactone | Spironolactone | 51 | 15 |
| Furosemide | Furosemide | 49 | 22 |
| Celecoxib | Celecoxib | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 15 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Memantine Hcl | Memantine Hcl | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 20 |
| Finasteride | Finasteride | 43 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 20 |
| Famotidine | Famotidine | 41 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 37 |
| Ramipril | Ramipril | 40 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Glimepiride | Glimepiride | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 13 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Prednisone | Prednisone | 32 | 26 |
| Ozempic | Semaglutide | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 13 |
| Valsartan | Valsartan | 30 | 12 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Prolia | Denosumab | 27 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Glipizide | Glipizide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | 12 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.61 · 28 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, KRYSTEXXA, Kerendia, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error